Amplified anticoagulant activity of tissue factor-targeted thrombomodulin

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 317-324

  Wang, Yi Xin ^a,b   Wu, Chenliang ^a   Vincelette, Jon ^a   Martin McNulty, Baby ^a   Alexander, Serene ^a   Larsen, Brent ^a   Light, David R ^a   McLean, Kirk ^a  

^a BAYER AG   (Germany)

^b NONE   (United States)

Author keywords

Anticoagulant; Fusion protein; Rat thromboembolism; Thrombomodulin; Tissue factor

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; PROTEIN C; THROMBIN; TISSUE FACTOR NEUTRALIZING ANTIBODY THROMBOMODULIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CALCULATION; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; GENE ACTIVATION; IN VITRO STUDY; MALE; MORTALITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SCORING SYSTEM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; THROMBOEMBOLISM; THROMBOMODULIN; THROMBOPLASTIN; TIME FACTORS;

EID: 33748627707     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-04-0219     Document Type: Article

References (35)

1. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004;79:103-8.
2. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.
3. Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-800.
4. McLean K, Schirm S, Johns A, et al. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res 2001; 103: 281-97.
5. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000; 157: 1849-62.
6. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
7. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
8. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89: 1-2.
9. Himber J, Refino CJ, Burcklen L, et al. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 200 1; 85: 475-81.
10. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. Faseb J 1995; 9: 946-55.
11. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995; 6: 259-68.
12. Esmon CT. Inflammation and thrombosis: the impact of inflammation on the protein C anticoagulant pathway. Haematologica 1995; 80 (Suppl 2): 49-56.
13. Esmon CT. Inflammation. They're not just for clots anymore. Curr Biol 1995; 5: 743-6.
14. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Clin Haematol 1994; 7: 453-68.
15. Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of antithrombin deficiency. Blood Rev 1996; 10: 59-74.
16. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
17. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996; 76: 824-34.
18. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
19. Taylor FB, Jr., Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
20. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999-1 82: 718-21.
21. McLean K, Masikat MR, Rumennik G, et al. Tissue factor targeted thrombomodulin (Ab(TF)-TM) - a novel tissue factor neutralizing antibody fused to thrombomodulin (TM). J Thromb Haemost 2005; 3 (Suppl 1): P1359.
22. Nemerson Y, Gentry R. An ordered addition, essential activation model of die tissue factor pathway of co-agulation: evidence for a conformational cage. Biochemistry 1986; 25: 4020-33.
23. Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000; 149: 251-66.
24. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989;9:2752-5.
25. Brand K, Fowler BJ, Edgington TS, et al. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11: 4732-8.
26. Chou J, Mackman N, Merrill-Skoloff G, et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
27. Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000; 10: 139-43.
28. Bogdanov VY, Balasubramanian V Hathcock J, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-62.
29. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-72.
30. Levy MM, Fink MP Marshall JC, et al. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
31. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 200 1; 29: 1303-10.
32. Zisman DA, Kunkel SL, Strieter RM, et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997; 8: 349-56.
33. Zisman DA, Kunkel SL, Stricter RM, et al. MCP-1 protects mice in lethal endotoxemia. J Clin Invest 1997; 99: 2832-6.
34. Bernard GR, Ely EW Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
35. Abendschein D, Wang Y-X, Light D, et al. Inhibition of thrombosis after vascular injury with a novel tissue factor-targeted thrombomodulin fusion protein. J Thromb Haemost 2005; 3 (Suppl 1): OR077.